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was studied by immunohistochemistry.  Results: Cardiac 
hepcidin messenger RNA (mRNA) expression was increased 
2-fold in CL (p = 0.03) and 3-fold in SNX (p = 0.01). Cardiac 
ferritin staining was not different among groups. Cardiac 
hepcidin mRNA expression correlated with mRNA expres-
sion levels of brain natriuretic peptide (β = 0.734, p < 0.001) 
and connective tissue growth factor (β = 0.431, p = 0.02). In 
contrast, liver hepcidin expression was unaffected by SNX 
and CL alone, while it had decreased 50% in SNX + CL (p < 
0.05). Hepatic ferritin immunostaining was not different 
among groups.  Conclusions: Our data indicate differences 
in hepcidin regulation in liver and heart and suggest a role 
for injury rather than iron as the driving force for cardiac hep-
cidin expression in renocardiac failure. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Iron-dependent modulation of energy metabolism is 
important in tissues with high metabolic demand, such as 
the myocardium  [1] . The mechanisms involved in local 
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 Abstract 
 Background: Hepcidin regulates systemic iron homeostasis 
by downregulating the iron exporter ferroportin. Circulating 
hepcidin is mainly derived from the liver but hepcidin is also 
produced in the heart. We studied the differential and local 
regulation of hepcidin gene expression in response to myo-
cardial infarction (MI) and/or chronic kidney disease (CKD). 
We hypothesized that cardiac hepcidin gene expression is 
induced by and regulated to severity of cardiac injury, either 
through direct (MI) or remote (CKD) stimuli, as well as 
through increased local iron content.  Methods: Nine weeks 
after subtotal nephrectomy (SNX) or sham surgery (CON), 
rats were subjected to coronary ligation (CL) or sham surgery 
to realize 4 groups: CON, SNX, CL and SNX + CL. In week 16, 
the gene expression of hepcidin, iron and damage markers 
in cardiac and liver tissues was assessed by quantitative 
polymerase chain reaction and ferritin protein expression 
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iron metabolism are of critical importance since both iron 
overload and iron deficiency have poor outcomes in the 
heart [2–4] . Hepcidin is the main regulatory protein of 
systemic iron metabolism. It is mainly produced in the 
liver and binds to ferroportin-1 (Fpn-1), a cellular iron 
exporter, resulting in internalization and degradation of 
the complex  [5] . Hepcidin thus inhibits cellular iron efflux 
from enterocytes, macrophages and hepatocytes  [6] . Be-
cause hepcidin synthesis is primarily controlled at the 
transcriptional level  [7] , hepcidin antimicrobial peptide 
(Hamp) messenger RNA (mRNA) expression level is a 
good indication of the amount of hepcidin peptide pro-
duced.
 Circulating hepcidin levels are mainly derived from 
the liver. Hepcidin is also expressed by other cells, such as 
the heart  [8, 9] , albeit at a much lower level by comparison 
 [10] . Locally produced hepcidin affects iron homeostasis 
in an autocrine fashion, as shown by the downregulation 
of Fpn-1 expression by hepcidin produced by inflamma-
tory monocytes  [11] . In vitro, hepcidin reduces Fpn-1 
content and iron release in cardiomyocytes  [12] , suggest-
ing that hepcidin is involved in regulating cardiac iron 
turnover. Previous studies show that myocardial isch-
emia induces cardiac hepcidin expression and conse-
quently enhances ferritin content in cardiomyocytes, this 
being related to the severity of ischemia  [8, 9] . This sug-
gests that, in addition to systemic regulation, hepcidin ex-
pression is also regulated at organ level and may influence 
cardiac iron content in response to myocardial injury. In-
deed, cardiac hepcidin expression is regulated by a num-
ber of factors including hypoxia and inflammation  [8] .
 Recently, we developed a rodent model of chronic 
renocardiac failure by subtotal nephrectomy (SNX) fol-
lowed by coronary ligation (CL)  [13] . CL superimposed 
on SNX leads to more severe heart failure. For the current 
study, we assessed cardiac and hepatic hepcidin mRNA 
expression and related regulatory genes as well as ferritin 
protein expression, an indicator of local iron stores in this 
model.
 The present study investigated the assumption that 
hepcidin expression in liver and heart is differentially reg-
ulated. We hypothesized that cardiac hepcidin is upregu-
lated in response to damage, both in models that induce 
damage to the myocardium directly (i.e., myocardial in-
farction (MI) induced by CL) as well as in models that 
damage the myocardium indirectly (i.e., chronic kidney 
disease (CKD) induced by renal ablation). Furthermore, 
we hypothesized that the induction of hepcidin gene ex-
pression is related to the severity of cardiac injury and 
increases local iron content.
 Methods 
 Study Design 
 The study protocol was approved by the Ethics Committee on 
Animal Experiments of the University of Utrecht, Utrecht, The 
Netherlands. Male inbred Lewis rats (Lew/Crl; 180–200 g) were 
purchased from Charles River, Germany, and housed in a climate-
controlled facility with a 12: 12-hour light:dark cycle. From t = –1 to 
week 0, a 2-stage SNX by resection or sham operation was per-
formed as described previously  [13] . Briefly, first the right kidney 
was removed, and 1 week later, the poles of the left kidney were cut 
off. Adequacy of the SNX procedure was confirmed by an increase 
in plasma urea. From t = 1 week onward, rats received standard 
powdered chow supplemented with 6% NaCl until the end of the 
study. In Lewis rats, high salt intake is required to induce fluid over-
load and hypertension after SNX  [13] . At t = 9 weeks, rats from both 
groups were either subjected to CL or sham operation. This resulted 
in 4 groups: CON (sham-SNX + sham-CL, n = 10), SNX (SNX + 
sham-CL, n = 12), CL (sham-SNX + CL, n = 9) and SNX + CL (n = 
9). Rats were followed up to week 16. To assess end diastolic volume 
(EDV), transthoracic echocardiography was performed with a dig-
ital ultrasound machine (model Sonos 5500, Philips Research, 
Eindhoven, The Netherlands) and a 15-MHz linear array transduc-
er (Hewlett Packard, Palo Alto, Calif., USA). CL and SNX + CL rats 
without visible MI on echocardiography and an ejection fraction 
(EF)  ≥ 40% at week 11 were excluded from the study. EF was calcu-
lated from end-diastolic and end-systolic volumes obtained with 
the area-length calculation, on B-mode cine loops recorded in the 
parasternal long axis view  [13] . In week 16, rats were subjected to 
isoflurane anesthesia, euthanized and organs were removed, 
weighed and processed for histological quantification and determi-
nation of mRNA expression. Left ventricular mass index (LVMI) 
was calculated as percentage of total body weight (BW, g/100 g). 
Infarct size was measured on photomicrographs of transverse sec-
tions of the heart stained with Sirius Red by dividing the length of 
the infarct scar by the circumference of the total LV section, traced 
in the midwall using ImageJ software. Fibrosis was measured on 
photographs of transverse sections (in remote myocardium of 
hearts with MI) stained with Sirius Red. Photographs were taken 
using a polarization filter and analyzed using Adobe Photoshop and 
ImageJ software. All measurements were performed by an experi-
enced technician blinded to the group allocation. The study proto-
col was approved by the Ethics Committee on Animal Experiments 
of the University of Utrecht, Utrecht, The Netherlands.
 Immunohistochemistry 
 Macrophages were stained with an antibody to ED1 and lym-
phocytes with an antibody to CD3 as previously described  [13] . 
ED1- and CD3-positive cells were counted in the left ventricle. 
Renal tissue was paraffin embedded and cut into 3-μ sections. 
Perls’ Prussian Blue staining was performed to assess iron deposi-
tion. Besides Prussian Blue as a histopathology stain, ferritin im-
munostaining was used in cardiac and liver tissue to detect the 
presence of iron. Paraffin sections were deparaffinized with xylene 
and rehydrated with a series of decreasing ethanol concentrations. 
Next, an antigen retrieval step using citrate was performed. To 
block endogenous peroxidise activity, the sections were incubated 
with 1% BSA. The primary antibody (rabbit anti-ferritin, Sigma-
Aldrich) was incubated overnight at 4  °  C in a 1: 50 dilution. A poly-
clonal biotinylated swine anti-rabbit immunoglobulin antibody 
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was used as secondary antibody in a 1: 500 dilution for 30 min at 
RT. Section were subsequently incubated for 30 min with an avidin 
biotin complex, followed by 3 min of 3.3 ′ -diaminobenzidine. 
Quantification of ferritin staining was done by means of calculat-
ing the reciprocal intensity using ImageJ software, with an average 
of 10 images per section  [14] . In all CL rats, immunohistochemis-
try was evaluated in regions distant from the infarct.
 RNA Isolation and Quantitative Polymerase Chain Reaction 
 mRNA expression of hepcidin (Hamp; Rn00221783), brain na-
triuretic peptide (Bnp; Rn00580641), connective tissue growth factor 
(Ctgf; Rn00573960), Fpn-1 (Slc40a1, Rn00591187), heme oxygen-
ase-1 (Ho-1; Rn00561387) and bone morphogenetic protein 6 
(Bmp6; Rn 00432095) in cardiac apical tissue (distant from the infarct 
in CL rats), and of hepcidin and CCAAT/enhancer binding protein 
α (C/ebp α; Rn00560963) in liver tissue was assessed by quantitative 
polymerase chain reaction (qPCR) as described previously  [15] .
 For the real-time PCR using the BIOMARK device (Fluidigm, 
San Francisco, Calif., USA), RNA was purified from 2 μg total RNA 
samples using the RNeasy Micro kit (Qiagen, Toronto, Canada) 
and genomic DNA was removed by RNase-free DNase (Qiagen). 
Quality and quantity of all RNA samples was using a Bio-Analyzer 
(Agilent, Santa Clara, Calif., USA). Reverse transcription was car-
ried out on 200–500 ng total RNA per sample using SuperScript ® 
II Reverse Transcriptase and random primers (Thermo Fisher Sci-
entific). The following TaqMan primers were used (all from Ther-
mo Fisher Scientific): calnexin (Canx; Rn01459976_m1), actin-β 
(Rn00667869_m1), interleukin (IL)-1β (IL-1β; Rn00580432_m1), 
IL-6 (Rn01410330_m1), caspase 3 (Rn00563902_m1), TNFR-1 
(Rn01492348_m1), TLR4 (Rn00569848_m1), C/EBP α 
(Rn00560963_s1), TNF α (Rn01525860_g1) and TLR2 
(Rn01769726_m1). Then, each primer was mixed with DNA sus-
pension buffer (TEKNOVA, Hollister, USA) and each cDNA sam-
ple was added. Following the addition of preamp master mix (Flu-
idigm), 14 circles of pre-amplification were performed on a ther-
mocycler (Bio-Rad, Hercules, Calif., USA). Then, the real-time 
PCR of each sample in duplicate was performed using the 10 prim-
ers in duplicate using a 48 * 48 IFC and the Fluidigm Biomark HD 
instrument. The data were collected and analyzed using the Fluid-
igm Data Collection system, and cycle time (Ct) values were calcu-
lated from the software of Biomark Real-Time PCR Analysis. For 
all samples, at least 4 successful reactions were obtained.
 Ct values for all genes were normalized to mean Ct values of 
Canx (Rn00596877) and β-actin (Rn00667869), which we previ-
ously determined to be the 2 most stable housekeeping genes across 
all groups in both organs using the geNorm program (http:// 
medgen.ugent.be/jvdesomp/genorm/). This produced ΔCt values. 
Gene expression relative to CON was calculated by subtracting the 
ΔCt values from the mean ΔCt of the CON group, producing the 
ΔΔCt values. Statistical analysis was performed on ΔΔCt values, 
and results were graphed as fold changes compared to CON (2 ΔΔCt ).
 Statistical Analysis 
 Data were analyzed and graphed using SigmaPlot 12.3 (Systat 
Software, San Jose, Calif., USA). Data that were not normally dis-
tributed were log-transformed to achieve normality. Statistical 
analysis was performed by 2-way analysis of variance (ANOVA) 
with the Student-Newman-Keuls post hoc test. Statistical signifi-
cance was reached with p values <0.05. Univariate linear regression 
was used to test correlations.
 Results 
 General Results 
 Longitudinal functional and structural characterization 
of this model has been published elsewhere  [13] . At week 
15, rats with SNX had lower BW than rats without SNX, 
which was not affected by subsequent CL ( table 1 ). SNX 
caused reduced creatinine clearance (p < 0.001 vs. CON) 
Table 1.  Biometric and terminal inflammation variables in the heart at week 15 [13]
Con (n = 10) CON + CL (n = 9) SNX (n = 10) SNX + CL (n = 7)
BW, g 424±8 426±9 378±11*** 361±14###
Hematocrit, ml/ml 0.47±0.01 0.46±0.01 0.42±0.01** 0.43±0.02
Kidney
Creatinine clearance, 
ml/min/100 g BW 0.74±0.06 0.67±0.09 0.30±0.03*** 0.27±0.04###
Heart
Cardiac index, ml/min/
100 g BW 30±2 17±1*** 29±2 14±1$$$
LVMI, g/100 g BW 0.19 (0.19–0.20, n = 8) 0.21 (0.20–0.23, n = 5) 0.35 (0.32–0.39, n = 7)*** 0.29 (0.26–0.30, n = 6)$$$, ***
EDV 0.54±0.03, n = 8 0.83±0.11, n = 5*** 0.70±0.06, n = 6 0.97±0.05, n = 6$$
CD3+ cells in myocardium 
(per HPF) 1.2 (0.1–2.8) 0.5 (0–1.4) 0.5 (0–1.9) 0.5 (0.2–1.6)
ED1+ cells in myocardium 
(per HPF) 11 (5–15) 16 (12–26)** 11 (7–22) 16 (5–25)
 Data as mean ± SEM and as median (range). HPF = High power field. ** p < 0.01 vs. CON, *** p < 0.001 vs. CON, ### p < 0.001 vs. CL, 
$$ p < 0.01 vs. SNX, $$$ p < 0.001 vs. SNX. Th ese data were published previously [13].
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that was not significantly affected by CL in either CL or 
SNX + CL rats. Given the differences in BW, cardiac param-
eters are expressed per 100 g BW, where applicable. Cardiac 
index was lower in SNX + CL than in SNX (p < 0.01) and 
tended to be lower in SNX + CL compared to CL (p = 0.065). 
LVMI increased in SNX rats (p < 0.001 vs. CON) but de-
creased in SNX + CL, while EDV increased only in CL (p < 
0.01 vs. CON) and SNX + CL rats (p < 0.01 vs. SNX).
 Immunohistochemistry 
 The number of inflammatory CD3-positive lympho-
cytes (T-cells) in the remote myocardium was not differ-
ent between groups ( table 1 ). Inflammatory ED1-positive 
cells (monocytes and macrophages) were increased in the 
remote myocardium after CL compared to CON (p  < 
0.01), irrespective of the presence of SNX.
 Hepcidin mRNA Expression in Heart and Liver 
 To investigate the differential regulation of hepcidin, 
we assessed hepcidin, that is,  Hamp , gene expression in 
both heart and liver tissues. Compared to CON, hepcidin 
mRNA expression in cardiac tissue was increased 2-fold 
in CL (p = 0.03) and 3-fold in SNX (p = 0.01;  fig. 1 ). In 
contrast, hepatic mRNA expression of hepcidin was unaf-
fected by SNX and CL alone, while it was significantly 
decreased (50%, p < 0.05) in SNX + CL compared to both 
SNX and CL alone.
 Iron Content in Heart and Liver 
 We used Prussian Blue staining to localize iron storage 
in heart tissue. In the remote myocardium of CL rats, 
practically no iron was observed, similar to hearts of non-
infarcted (SNX or CON) rats. To extend our observa-
tions, we also performed ferritin immunohistochemistry. 
In line with the Prussian Blue staining, no differences in 
ferritin content in the remote myocardium of CL and 
SNX + CL rats as compared to non-infarcted rats were 
observed ( fig. 2 a). In liver tissue, there were also no dif-
ferences seen in ferritin content in CL and SNX + CL rats 
compared to SNX or CON ( fig. 2 b).
 Cytokine Expression in Cardiac Tissue 
 To confirm that inflammation was related to cardiac 
hepcidin expression, we measured cardiac cytokine gene 
expressions involved in inflammation and apoptosis. 
Cardiac gene expression of IL-6, IL-1β, caspase 3 and 
Canx tended to increase in SNX and CL, but the only 
gene expression reaching statistical significance was IL-
1β. Both SNX and CL independently increased cardiac 
IL-1β gene expression (increase 6-fold, p < 0.001 and in-
crease 8-fold, p < 0.001, respectively;  fig. 3 ). The combi-
nation of both SNX and CL did not further increase car-
diac IL-1β gene expression.
 Bmp6 mRNA Expression in Cardiac Tissue 
 The extracellular signaling molecule Bmp6 enhances 
transcription of the hepatic hepcidin gene in mice  [16] . 
Cardiac Bmp6 mRNA expression level followed the same 
pattern as cardiac hepcidin mRNA expression. Bmp6 was 
significantly increased in SNX rats (p < 0.01), while the 
largest increase was seen in SNX + CL rats ( fig. 4 ).
 Cardiac BNP and CTGF mRNA Expression 
 In order to investigate the degree of damage in cardiac 
tissue, we measured Bnp and Ctgf mRNA expression levels 






























































 Fig. 1. Hepcidin mRNA expression in heart ( a ) and liver ( b ). ΔΔCt: 
Ct values of target gene normalized to mean Ct values of house-
keeping genes and the mean Ct value of the CON group. Mean ± 
SEM,  * p < 0.05 vs. CON,  # p < 0.05 vs. CL,  $ p < 0.05 vs. SNX. N 
heart: CON 9, CL 6, SNX 7, SNX + CL 6. N liver: CON 8, CL 7, 
SNX 8, SNX + CL 4. 
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 Fig. 2. Quantification of ferritin staining assessed by immunohistochemistry and representative images of ferritin 
in cardiac tissue ( a ) and liver tissue ( b ). N heart: CON 5, CL 4, SNX 4, SNX + CL 4. N liver: CON 4, CL 4, SNX 
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***
 Fig. 3. IL-1β expression in cardiac tissue, assessed by qPCR. ΔΔCt: 
Ct values of target gene normalized to mean Ct values of housekeep-
ing genes and the mean Ct value of the CON group. Mean ± SEM, 

























 Fig. 4. Bmp6 expression in cardiac tissue, assessed by qPCR. ΔΔCt: 
Ct values of target gene normalized to mean Ct values of house-
keeping genes and the mean Ct value of the CON group. Mean ± 
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Bnp were increased 2.2- and 1.8-fold in SNX and in CL rats, 
respectively, with a 2.8-fold increase in SNX + CL as re-
ported  [13] . Cardiac mRNA expression levels of Ctgf were 
increased 45- and 18-fold in SNX and in CL rats, respec-
tively, with a 61-fold increase in SNX + CL as reported  [13] .
 Ho-1 and Fpn-1 mRNA Expression in Cardiac Tissue 
 To get more insight about regulation of iron in the 
heart, we assessed mRNA expression levels of other pro-
teins involved in iron metabolism such as Ho-1 and Fpn-
1  [17] . It is well known that Ho-1 acts as an antioxidant 
against oxidative injury, which could inhibit the produc-
tion of reactive oxygen species (ROS) and reduce oxida-
tive damage  [18, 19] . Cardiac mRNA expression of Ho-1 
was significantly increased in SNX (p < 0.01 vs. CON). 
Ho-1 expression level in SNX + CL tended to be lower 
than SNX and resembled the level of CL ( fig. 5 a). Cardiac 
mRNA expression of Fpt1 showed the same pattern as 
Ho-1, with a stepwise increase in CL and SNX. Similar to 
Ho-1, Fpn-1 gene expression in SNX + CL was less than 
in SNX and similar to CL. Two-way ANOVA showed sig-
nificant interaction between SNX and CL ( fig.  5 b; p  = 
0.002).
 Hepatic mRNA Expression of C/EBP α 
 Since C/ebp α plays a key role in regulation of Hamp 
gene expression in the liver  [20] , we expected the same 
pattern for hepatic C/ebp α mRNA expression as for he-
patic hepcidin mRNA expression. Indeed, hepatic mRNA 
expression of C/ebp α decreased progressively across 
groups with the largest decrease in SNX + CL (p < 0.05 vs. 
CL and p < 0.05 vs. SNX;  fig. 6 ).
 Correlations 
 In order to investigate possible factors influencing car-
diac and hepatic hepcidin expression, correlations were 
analyzed. Cardiac hepcidin mRNA expression correlated 
linearly with Bnp mRNA expression (β = 0.73, p < 0.001; 
 fig. 7 a) and Ctgf mRNA expression (β = 0.43, p = 0.02; 
 fig. 7 b) but not with Bmp6 mRNA expression (β = 0.23, 
p  = 0.25;  fig.  7 c). Cardiac hepcidin mRNA expression 
strongly correlated with pro-inflammatory cytokine IL-





























































Fig. 5. Ho-1 expression ( a ) and Fpn-1 expression ( b ) in cardiac 
tissue, assessed by qPCR. ΔΔCt: Ct values of target gene normal-
ized to mean Ct values of housekeeping genes and the mean Ct 
value of the CON group. Mean ± SEM,  * p < 0.05 vs. CON,  * * p < 
0.01 vs. CON,  * * * p < 0.001 vs. CON,  $ p < 0.05 vs. SNX. N: CON 

































 Fig. 6. Hepatic expression of c/EBP α across groups. ΔΔCt values 
of target gene normalized to mean Ct values of housekeeping genes 
and the mean Ct value of the CON group. Mean ± SEM,  * p < 0.05 
vs. CON,  # p < 0.05 vs. CL,  $ p < 0.05 vs. SNX. N: CON 9, CL 7, 
SNX 9, SNX + CL 4. 
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mRNA expression did not correlate with cardiac ferritin 
immunostaining (β = 0.16, p = 0.54).
 Hepatic hepcidin mRNA expression correlated with 
hepatic mRNA expression of the transcription factor 
C/ ebp α (β = 0.68, p < 0.001;  fig. 8 ) but not with ferritin 
staining (β = 0.14, p = 0.64).
 Both LVMI and EDV correlated significantly with 
cardiac hepcidin mRNA expression (β = 0.53, p < 0.01 
and β = 0.62, p < 0.001, respectively;  fig. 9 a, b). The cor-
relation between cardiac hepcidin mRNA expression 
and percentage of Sirius Red stained area as a measure of 
cardiac fibrosis was not significant (β  = 0.35, p  = 0.1; 
 fig. 9 c).
 Discussion 
 The aim of this study was to investigate regulation of 
hepcidin at tissue level in experimental chronic renocar-
diac failure. The main finding of this study was that car-
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R = 0.734, p < 0.001
R = 0.228, p = 0.254 R = 0.471, p = 0.02
R = 0.431, p = 0.02
 Fig. 7. Correlations between cardiac expression of hepcidin and Bnp ( a ), cardiac hepcidin and Ctgf ( b ), cardiac 
hepcidin and Bmp6 ( c ) and cardiac hepcidin and IL-1β ( d ). ΔΔCt values of target gene normalized to mean Ct 
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R = 0.682, p < 0.001
 Fig. 8. Correlation between hepatic gene expression of c/EBP α and 
hepatic hepcidin. ΔΔCt values of target gene normalized to mean 
Ct values of housekeeping genes and the mean Ct value of the CON 
group. 
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duced in both local (CL inducing MI) and remote (SNX 
inducing CKD) injury. Conversely, liver hepcidin gene 
expression was decreased. Cardiac iron content in non-
infarcted tissue remained unchanged in all experimental 
groups. Thus, cardiac hepcidin expression was increased 
in response to injury, but no evidence of an association 
with local iron accumulation was observed.
 The increased cardiac expression of hepcidin is in 
agreement with findings in other models with cardiac 
injury and myocarditis  [8, 9, 21] . In rats, hypoxia and 
inflammation were shown to upregulate hepcidin ex-
pression  [8] . In agreement with this finding, hepcidin 
expression was found to be induced in rat hearts with MI 
and myocarditis, as well as in human hearts with myo-
carditis  [9] . Furthermore, increased expression of hep-
cidin was found in the hearts of rats with CKD, which 
was associated with levels of iron deficiency and anemia 
 [21] .
 We assessed the mRNA expression of the cardiac dam-
age markers Bnp and Ctgf in myocardial tissue. Bnp is a 
well-known marker of cardiac dysfunction and has an 
anti-fibrotic function  [22] , and Ctgf is a profibrotic cyto-
kine of the Ccn (Cyr61, Ctgf and Nov) family  [23] and is 
suggested to serve as a diagnostic marker of cardiac dys-
function  [24, 25] . As shown, there is a progressive in-
crease of Bnp and Ctgf gene expression in the CL, SNX 
and SNX + CL group. Cardiac hepcidin expression in the 
SNX + CL group was significantly and positively corre-
lated with cardiac injury based on Bnp and Ctgf but not 
with ferritin staining. Based on these findings, we postu-
late that cardiac hepcidin mRNA expression can be in-
duced by local or remote injury and is not necessarily de-
pendent on local iron stores. In the remote myocardium, 
even though there is no evidence of direct myocardial 
damage and iron accumulation, hepcidin expression is 
upregulated.
 To confirm our hypothesis that local injury in the 
heart affects cardiac hepcidin gene expression, we mea-
sured the expression of several inflammatory cytokine 
gene expressions in the heart. Although the cardiac gene 
expression of IL-6, IL-1β, caspase 3 and Canx tended to 
increase in SNX and CL, suggesting inflammation and 
apoptosis, the only gene expression that reached statisti-
cal significance is IL-1β. High blood levels of IL-1β have 
been observed after MI  [26] and it is demonstrated that 
IL-1β induces myocyte hypertrophy  [27] . Interestingly, 
IL-1β also increased in the SNX group. The pathophysi-
ological mechanism of renal failure and increased cardiac 
IL-1β expression is not elucidated. In experimental mod-
els of nephrotic syndrome, glomerular expression of IL-
1β is demonstrated  [28] , probably due to systemic inflam-
mation. Moreira-Rodrigues et al.  [29] showed elevated 
expression of cardiac IL-1β expression in a rat model with 
nephrotic syndrome, and high levels of IL-1β were mea-
sured in the kidneys of rats with spontaneous hyperten-
sion [30]. The strong correlation between cardiac hepci-
din gene expression and cardiac IL-1β supports the 
thought that cardiac hepcidin regulation is driven by in-
flammation instead of iron.
 Several authors speculate that hepcidin plays an im-
portant protective role against extracellular free radical 
formation since it decreases the presence of the trans-
membrane iron exporter ferroportin and thus inhibits 
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in cardiomyocytes, destruction of these cells could result 
in high iron concentrations in the extracellular space. It 
is well known that free iron generates damaging ROS and 
causes various types of injury  [31] , including myocardial 
fibrosis. Intracellular iron is stored in ferritin, an impor-
tant intracellular iron sequestering and storage protein 
that plays a cytoprotective role against free radical forma-
tion by controlling the free cytosolic iron concentration 
 [32] . It could be that during myocardial damage, cardiac 
hepcidin is upregulated to prevent iron release from the 
intact cells. However, in contrast to this possible mecha-
nism, in our study, cardiac ferritin content was not re-
lated to hepcidin expression. Our data suggest that hep-
cidin gene expression is influenced by local injury not re-
lated to local iron turn over; there is enhanced cardiac 
hepcidin mRNA expression in the absence of changed 
cardiac ferritin content. Besides, liver expression of Bmp6 
is transcriptionally regulated by iron – overload of iron 
increases Bmp6 expression, iron deficiency represses 
Bmp6 expression  [33] . However, in our study, cardiac 
BMP6 mRNA expression was significantly increased in 
SNX and SNX + CL rats, but no differences in iron con-
tent in the remote myocardium was observed. This could 
implicate that in the heart, it is not iron, but other stimu-
li such as injury, which stimulate Bmp6 expression. Bmp6 
expression could be part of a compensatory mechanism 
in the heart to stimulate cardiomyocyte hypertrophy  [34] . 
Korf-Klingebiel et al.  [34] found that recombinant Bmp6 
(even in low concentrations) resulted in a robust increase 
in cell size and protein synthesis in neonatal and adult 
cardiomyocytes, respectively.
 In contrast to hepcidin and the damage markers Bnp 
and Ctgf, and contrary to our expectations, Fpn-1 and 
Ho-1 mRNA expression showed a different pattern. For 
Fpn-1 and Ho-1, there was an interaction between SNX 
and CL, in that the presence of both eliminated the SNX 
effect. The basis for this observation is not clear. Although 
it is widely assumed that hepcidin induces ferroportin in-
ternalization and degradation, this relation is not as clear 
as it seems. In monocytes of HD patients, no correlation 
between serum hepcidin and ferroportin was found  [35] . 
This suggests that factors other than hepcidin also affect 
ferroportin levels and internalization and that degrada-
tion of ferroportin can take place in a hepcidin-indepen-
dent manner. The fact that this relation is absent in cell 
types in which hepcidin is thought to play its classical role 
(ferroportin internalization and degradation) supports 
our result regarding the lack of such a relation at the 
mRNA level in the heart in our cardiorenal syndrome 
model.
 Unexpectedly, combined SNX and CL showed a de-
crease in hepatic hepcidin mRNA expression. Both car-
diac and renal failure is associated with an increase of 
inflammatory cytokines, which could have resulted in an 
upregulation of hepatic hepcidin gene expression  [36] . 
However, several studies reported low serum hepcidin 
levels in patients with chronic heart failure and anemia 
 [ 37,  38] . One possible explanation is that iron deficiency, 
even in the presence of increased cytokines, leads to di-
minished levels of hepcidin in conditions of heart failure 
and anemia. Although in our rodent model only mild 
anemia was present, anemia and increased erythropoiesis 
(i.e., production of red blood cells) could downregulate 
the synthesis of hepcidin mRNA  [39] . Unfortunately, we 
did not measure circulating inflammatory cytokines and 
iron markers to confirm this hypothesis.
 In agreement with this finding, we showed a correla-
tion between mRNA expressions of C/ebp α and hepcidin 
in the liver, in the sense that both were reduced. C/ebp α 
is a transcription factor in the liver that has a positive ef-
fect on Hamp promoter activity  [20] . Alcoholic and viral 
liver cell damage both reduce hepcidin expression, a re-
duction which is mediated by ROS via C/ebp α  [40, 41] . 
Reduction in hepatic C/ebp α mRNA expression in reno-
cardiac failure may associate with hepatic oxidative stress 
 [42] .
 LVMI increased in SNX rats and decreased in SNX + 
CL rats, most probably due to the loss of cardiomyocytes 
after cardiac injury. As a measure of cardiac preload and 
increased filling pressures, EDV increased in CL and 
SNX  + CL rats. These results are in line with previous 
findings that LVMI increases during renal and cardiac 
failure, the predominant pattern being eccentric left ven-
tricular hypertrophy  [43, 44] . In accordance with previ-
ous research  [45] , the significant correlation between car-
diac hepcidin mRNA expression and LVMI and EDV 
suggests that hepcidin plays a role in the hypertrophic 
response in cardiomyocytes. Once again, this emphasizes 
the role of hepcidin in cardiac damage.
 Given the fact that liver hepcidin is only regulated at 
the transcriptional level, we used HAMP mRNA levels to 
detect cardiac hepcidin. Accordingly, we studied the 
stimulatory effect of cardiac injury on cardiac hepcidin 
expression rather than the reverse.
 In conclusion, cardiac expression of hepcidin is differ-
entially regulated in this rat model of renocardiac failure 
from its primary source of production, the liver. More-
over, our data suggest a role for injury rather than iron as 
a driving force for cardiac hepcidin expression in experi-
mental renocardiac failure. Future animal and cell exper-
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iments should be developed to study the mechanisms of 
systemic and local hepcidin production and action in dif-
ferent tissues. Elucidating the pathophysiological mecha-
nisms of local hepcidin regulation in patients with CKD 
and/or heart failure may help designing new therapeutic 
approaches.
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